10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Janssen has received European Commission (EC) marketing authorization for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (DRd) for the treatment of newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant (ASCT). 20 November 2019
US pharma major Bristol-Myers Squibb has announced that its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) has failed to meet a primary endpoint in the CheckMate -915 Phase III melanoma trial. 20 November 2019
Australians living with non-small cell lung cancer and early stage acute lymphoblastic leukemia will be able to access better treatment options with new listings on the Pharmaceutical Benefits Scheme (PBS) coming into effect on December 1, 2019. 20 November 2019
Shares in CRISPR Therapeutics and Vertex Pharmaceuticals closed up by 17% and 2% respectively on Tuesday after they presented data from an ongoing Phase I/II study. 20 November 2019
Shares in The Medicines Company have been boosted by reports that Swiss drugmaker Novartis (NOVN: VX) is considering making a bid on the firm. 20 November 2019
Shares of US biotech CNS Pharmaceuticals gained 4.1% to $4.33 yesterday, after revealing that it has completed an agreement with Houston Pharmaceuticals Inc (HPI) to obtain the rights to a worldwide, exclusive royalty-bearing, license for the chemical compound commonly known as berubicin. 20 November 2019
Industry analyst GlobalData has highlighted the significance of the POSEIDON study for AstraZeneca’s hopes in non-small-cell lung carcinoma (NSCLC). 19 November 2019
Ireland-incorporated biotech Alkermes has filed a New Drug Application (NDA) to the US Food and Drug Administration seeking approval of ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophrenia and for the treatment of bipolar I disorder. 19 November 2019
The PD-1 inhibitors space has become extremely competitive, but the latest data show that there is now an out-right winner in terms of revenue generation. 19 November 2019
Israeli drugmaker Protalix BioTherapeutics closed 40% up on Monday amid good news for pegunigalsidase alfa, the Fabry disease candidate that it is advancing alongside its development and commercialization partner, Chiesi Farmaceutici. 18 November 2019
In what is its first outright M&A deal in two decades, Ireland-incorporated biotech firm Alkermes has entered into a definitive agreement to acquire Rodin Therapeutics, a privately held biopharmaceutical company focused on developing novel, small molecule therapeutics for synaptopathies 18 November 2019
Shares in Boston biotech resTORbio were worth 86% less by Friday’s close after the announcement of top-line data from the Phase III study on the company’s lead candidate. 18 November 2019
East Coast, USA-based drug developer Dicerna Pharmaceuticals has inked an agreement with Denmark’s Novo Nordisk (NOV: N) to discover and develop novel therapies for liver-related cardio-metabolic diseases. 18 November 2019
With the US Centers for Disease Control and Prevention (CDC) report on antimicrobial resistance (AMR) stating that it is a much larger and more severe public health threat than previously thought, the AstraZeneca spin-out Entasis Therapeutics (Nasdaq: ETTX) has called for policy change. 18 November 2019
The US Food and Drug Administration on Friday approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients aged 16 years and older. 18 November 2019
Weeks after presenting positive Phase III trial results on the company’s key pipeline candidate, bimekizumab, UCB has proven that the first study was no fluke. 15 November 2019
The importance of the year ahead for US biopharma BioMarin Pharmaceutical was made abundantly clear at the company’s R&D Day in New York on Thursday. 15 November 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024